Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery perspective)

References

• 1. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer. 19(3), 133–150 (2019).
  Medline CASGoogle Scholar
• 2. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010).
  Medline CASGoogle Scholar
• 3. Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7(1), 278 (2019).
  MedlineGoogle Scholar
• 4. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016).
  Medline CASGoogle Scholar
• 5. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).
  Medline CASGoogle Scholar
• 6. Paz-Ares L, Luft A, Vicente D, Tafreshi A et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018).
  Medline CASGoogle Scholar
• 7. Schmid P, Rugo HS, Adams S et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 21(1), 44–59 (2019).
  MedlineGoogle Scholar
• 8. Burtness B, Harrington KJ, Greil R et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212), 1915–1928 (2019).
  Medline CASGoogle Scholar
• 9. Chung HC, Ros W, Delord JP et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the Phase II KEYNOTE-158 study. J. Clin. Oncol. 37(17), 1470–1478 (2019).
  Medline CASGoogle Scholar
• 10. Luchini C, Bibeau F, Ligtenberg MJL et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann. Oncol. 30(8), 1232–1243 (2019).
  Medline CASGoogle Scholar
• 11. Le DT, Durham JN, Smith KN et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017).
  Medline CASGoogle Scholar
• 12. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377(25), 2500–2501 (2017).
  MedlineGoogle Scholar
• 13. George AP, Kuzel TM, Zhang Y et al. The discovery of biomarkers in cancer immunotherapy. Comput. Struct. Biotechnol. J. 17, 484–497 (2019).
  MedlineGoogle Scholar
• 14. Fancello L, Gandini S, Pelicci PG et al. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J. Immunother. Cancer 7(1), 183 (2019).
  MedlineGoogle Scholar
• 15. Büttner R, Longshore JW, López-Ríos F et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 4(1), e000442 (2019).
  MedlineGoogle Scholar
• 16. Skoulidis F, Arbour KC, Hellmann MD et al. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J. Clin. Oncol. 37(Suppl. 15), 102 (2019).
  Google Scholar
• 17. Mezquita L, Gataa I, Rossoni C et al. MA25.03 tumor-infiltrating lymphocytes (TIL) and outcomes with immunotherapy (ICI) or chemotherapy in advanced NSCLC (aNSCLC) patients. J. Thorac. Oncol. 14(10), S351–S352 (2019).
  Google Scholar
• 18. Mariathasan S, Turley SJ, Nickles D et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693), 544–548 (2018).
  Medline CASGoogle Scholar
• 19. Ayers M, Lunceford J, Nebozhyn M et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127(8), 2930–2940 (2017).
  MedlineGoogle Scholar
• 20. Arora S, Velichinskii R, Lesh RW et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv. Ther. 36(10), 2638–2678 (2019).
  MedlineGoogle Scholar